How are NKTR strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NKTR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 56.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$542.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a NKTR strangle?

The breakeven for the NKTR strangle priced on this page is roughly $59.58 and $80.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTR market-implied 1-standard-deviation expected move is approximately 16.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current NKTR implied volatility affect this strangle?

NKTR ATM IV is at 56.90% with IV rank near 3.34%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

NKTR Strangle Strategy

NKTR (Nektar Therapeutics), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR (Nektar Therapeutics) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.48B, a beta of 1.25 versus the broader market, a 52-week range of 7.99-109, average daily share volume of 1.1M, a public-listing history dating back to 1994, approximately 61 full-time employees. These structural characteristics shape how NKTR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.25 places NKTR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on NKTR?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current NKTR snapshot

As of May 15, 2026, spot at $70.12, ATM IV 56.90%, IV rank 3.34%, expected move 16.31%. The strangle on NKTR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on NKTR specifically: NKTR IV at 56.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a NKTR strangle, with a market-implied 1-standard-deviation move of approximately 16.31% (roughly $11.44 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTR expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTR should anchor to the underlying notional of $70.12 per share and to the trader's directional view on NKTR stock.

NKTR strangle setup

The NKTR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTR near $70.12, the first option leg uses a $75.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTR shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$75.00	$3.08
Buy 1	Put	$65.00	$2.35

NKTR strangle risk and reward

Net Premium / Debit: -$542.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$542.50
Breakeven(s): $59.58, $80.43
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

NKTR strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on NKTR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$5,956.50
$15.51	-77.9%	+$4,406.22
$31.02	-55.8%	+$2,855.94
$46.52	-33.7%	+$1,305.66
$62.02	-11.5%	-$244.63
$77.52	+10.6%	-$290.09
$93.03	+32.7%	+$1,260.19
$108.53	+54.8%	+$2,810.47
$124.03	+76.9%	+$4,360.75
$139.54	+99.0%	+$5,911.03

When traders use strangle on NKTR

Strangles on NKTR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NKTR chain.

NKTR thesis for this strangle

The market-implied 1-standard-deviation range for NKTR extends from approximately $58.68 on the downside to $81.56 on the upside. A NKTR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NKTR IV rank near 3.34% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NKTR at 56.90%. As a Healthcare name, NKTR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTR-specific events.

NKTR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTR alongside the broader basket even when NKTR-specific fundamentals are unchanged. Always rebuild the position from current NKTR chain quotes before placing a trade.

Frequently asked questions

What is a strangle on NKTR?: A strangle on NKTR is the strangle strategy applied to NKTR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NKTR stock trading near $70.12, the strikes shown on this page are snapped to the nearest listed NKTR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are NKTR strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NKTR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 56.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$542.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NKTR strangle?: The breakeven for the NKTR strangle priced on this page is roughly $59.58 and $80.43 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTR market-implied 1-standard-deviation expected move is approximately 16.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on NKTR?: Strangles on NKTR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NKTR chain.
How does current NKTR implied volatility affect this strangle?: NKTR ATM IV is at 56.90% with IV rank near 3.34%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.